|
Status |
Public on Sep 01, 2021 |
Title |
Effects of durvalumab alone or combined with tremelimumab on preexisting cells in the tumor microenvironment |
Organism |
Homo sapiens |
Experiment type |
Expression profiling by high throughput sequencing
|
Summary |
Immune checkpoint blockade with anti–PD-1/L1 or anti–CTLA-4 therapies has shown promising results across multiple cancer types, but the mechanisms within the tumor microenvironment (TME) have not been fully characterized. We used single-cell RNA sequencing to investigate the effects of anti–PD-L1 monoclonal antibody (mAb) durvalumab (D) alone and combined with an anti–CTLA-4 mAb, tremelimumab (T), on distinct subsets of immune cells. Upon treatment with D or D+T, two NSCLC tumors showed elevated IFNγ responses, although they differed in magnitude of response but differed in other areas. Our results highlight that D and D+T in the TME have some consistent effects across tumors but also exhibit tumor-specific effects depending on composition and functional state of immune cells in the TME at time of treatment. This complex tumor-specific interplay of diverse immune subtypes in the TME is critical to better understand patient response to immunotherapy.
|
|
|
Overall design |
Two tumors were treated by Durva and Durva+Treme and underwent single cell sequencing. RNA sequencing of 97 advanced-stage non–small-cell lung carcinoma (NSCLC) biopsies from a nonrandomized phase 1b/2 clinical trial (1108/NCT01693562) were profiled to identify expression of genes of interest.
|
|
|
Contributor(s) |
Shrestha Y |
Citation missing |
Has this study been published? Please login to update or notify GEO. |
Submission date |
May 29, 2019 |
Last update date |
Sep 01, 2021 |
Contact name |
Yinong Sebastian |
E-mail(s) |
sebastiany@medimmune.com
|
Organization name |
Medimmune
|
Street address |
One MedImmune Way
|
City |
Gaithersburg |
ZIP/Postal code |
20878 |
Country |
USA |
|
|
Platforms (1) |
GPL24676 |
Illumina NovaSeq 6000 (Homo sapiens) |
|
Samples (8)
|
|
Relations |
BioProject |
PRJNA545340 |
SRA |
SRP199793 |